For Alyssa L., PanCAN's Associate Director of Philanthropic Engagement and Mid-level Giving, the mission to advance pancreatic cancer research and support patients and families hits close to home. 💜
She shares, "In January 2025, my dad was diagnosed with pancreatic cancer.
I knew what people said about this disease. I had watched his mom, my grandmother, die just four months after her diagnosis in 2011. So, devastated, my dog and I moved home to make the most of the time we had left together.
His initial diagnosis was stage IB. But when a Whipple procedure attempt in June 2025 revealed two small lesions in his liver, he was immediately elevated to stage IV, and the doctor estimated that he likely had only eight months to a year left.
Since then, our family has been through more rounds of chemotherapy than I can count,
CT scans, infections, a second failed Whipple surgery, setbacks and the agonizing uncertainty of waiting for results, return phone calls and the next appointment.
If you’ve been touched by pancreatic cancer, you likely recognize this cycle of hope and grief. I knew I needed something that would get me out of bed in the morning. I felt desperate to contribute something positive and make meaningful progress for others facing this disease. That determination led me to PanCAN.
Since joining the team here, I haven’t just learned about PanCAN’s mission and programs. I’ve experienced their impact firsthand. I’ve used PanCAN’s website and resources to become better informed. I’ve attended every webinar and listened to PancChat podcasts to deepen my understanding of the disease, the science and the treatment landscape.
I attended my first PanCAN PurpleStride with my family and connected with other patients and caregivers, heard inspiring stories from survivors and experienced the power of a community united by hope. In conversations with our fundraising team, I’ve felt the authenticity, kindness and compassion that compels our supporters to give.
My colleagues in PanCAN Patient Services answered my many questions, which strengthened both my work and helped me navigate conversations with my dad’s care team with far more clarity and confidence.
When I prepared narratives about daraxonrasib and PanCAN’s decades-long role in propelling RAS research forward, I leaned heavily on my colleagues’ expertise to grasp the significance of this breakthrough. They also helped me understand the trial results and what they could mean for patients like my dad.
So, when another liver lesion finally showed up on his imaging this July, I already knew our next step: trying to get him into the expanded access program (EAP) for daraxonrasib. On August 25th, when his paperwork was finally submitted, I felt hopeful knowing we were on the path to keep just barely outrunning this cancer for a little while longer.
The next day, RASONQUE™ (daraxonrasib) was approved by the FDA.
As PanCAN shared the exciting news, I was simultaneously panicking about what it might mean for my dad’s access, particularly after a month off treatment.
Luckily, PanCAN’s Patient Services team provides personalized guidance for people exactly like me. I called, and they knew what my next steps should be. On their guidance, we got back on track to access the treatment through insurance.
Colleagues had already been checking in because they knew others were running into access issues, and they were hard at work telling the story of how to better advocate for patients and their loved ones.
So I wasn’t all that surprised when my dad was denied coverage.
After a firm discussion with the insurance company, and armed with the knowledge I’d gained from Patient Services, we received a reversal — and RASONQUE arrived at our door the next day.
My dad’s been on RASONQUE for a month, and his numbers are looking good. I know RASONQUE isn’t a cure. But right now, this treatment is giving my family renewed hope for more time.
For more than 27 years, PanCAN President and CEO Julie Fleshman and Founder Pamela Acosta Marquardt have brought passion, unwavering dedication and ingenuity to PanCAN’s mission. Their commitment has been relentless, shaping and strengthening the field in countless ways. PanCAN’s willingness to be bold and innovative, to invest in RAS research 20 years ago when those mutations were considered undruggable, played a role in getting us to this moment. And the work we’re advancing today will continue to drive future breakthroughs for patients.
I’m so honored to be a part of it.
To my colleagues at PanCAN — and to everyone who donates, volunteers, walks, and advocates — you are changing people’s lives.
I know, because I’m one of them."
Join us in sharing some love and support for Alyssa and her family in the comments. 💜